Truist Financial Downgrades Exelixis(EXEL.US) to Hold Rating, Raises Target Price to $54Market news · 25 Jun 2026
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Kiora Pharmaceuticals (KPRX) and MAIA Biotechnology, Inc. (MAIA)TipRanks · 22 Jun 2026
Stifel Maintains Exelixis(EXEL.US) With Hold Rating, Announces Target Price $47Market news · 7 May 2026
H.C. Wainwright Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $56Market news · 7 May 2026
A Quick Look at Today's Ratings for Exelixis(EXEL.US), With a Forecast Between $45 to $55Market news · 6 May 2026
Discussion
No comments yet — be the first to weigh in on EXEL.
No comments yet — be the first to weigh in on EXEL.